Roche and Zealand Pharma Report P-II (ZUPREME-1) Trial Data on Petrelintide in Obesity

Why It Matters

Petrelintide’s robust efficacy signals a potential new therapeutic class for obesity, a market seeking alternatives to existing GLP‑1 agents. Successful Phase‑III outcomes could reshape treatment algorithms and capture significant market share.

Key Takeaways

• Phase II showed ~10.7% weight loss versus 1.7% placebo.
• Five dose levels all achieved significant reductions at week 28.
• Female participants experienced greater weight loss than males.
• 98% of patients reached maintenance dose by week 42.
• Data will shape upcoming Phase III and combination studies.

Pulse Analysis

Obesity remains a leading driver of chronic disease, and the pharmaceutical landscape is dominated by GLP‑1 receptor agonists. Yet unmet needs persist, especially for patients who experience suboptimal response or adverse effects. Amylin analogs like petrelintide offer a complementary mechanism by modulating satiety signals and gastric emptying, positioning them as potential game‑changers in weight‑management portfolios. The ZUPREME‑1 trial’s impressive 10.7% mean weight reduction underscores the therapeutic promise of targeting the amylin pathway alongside existing options.

The Phase‑II study enrolled nearly 500 participants with a mean BMI of 37 kg/m², reflecting a high‑risk population with comorbidities. Across five escalating weekly doses, participants achieved statistically significant weight loss as early as week 28, and the effect persisted through week 42. Notably, women experienced a larger magnitude of loss, hinting at possible sex‑specific pharmacodynamics that could inform dose optimization. Safety data, extended through a nine‑week follow‑up, were reassuring, and 98% of subjects successfully transitioned to the maintenance regimen, indicating good tolerability and adherence.

Looking ahead, the topline data will shape the design of a pivotal Phase‑III trial, while a parallel study in obese patients with type‑2 diabetes (ZUPREME‑2) is slated for H2 2026. A combination trial pairing petrelintide with CT‑388 later in 2026 suggests a strategic move toward multi‑modal obesity therapies. If Phase‑III confirms efficacy and safety, petrelintide could capture a sizable share of the rapidly expanding anti‑obesity market, challenging incumbents and expanding treatment options for clinicians and patients alike.